vs
CollPlant Biotechnologies Ltd（CLGN）与Sanara MedTech Inc.（SMTI）财务数据对比。点击上方公司名可切换其他公司
Sanara MedTech Inc.的季度营收约是CollPlant Biotechnologies Ltd的153.7倍（$27.5M vs $179.0K）。Sanara MedTech Inc.净利率更高（-5.9% vs -1869.8%，领先1864.0%）。Sanara MedTech Inc.同比增速更快（4.6% vs -28.1%）
CollPlant Biotechnologies是一家再生医疗企业，依托专有的植物源人胶原蛋白技术，开发并商业化伤口护理、软组织修复、医美领域的创新产品，主要面向北美、欧洲及以色列市场，服务皮肤科、骨科和医美领域的医疗从业者。
Sanara MedTech Inc.是一家总部位于美国的医疗科技企业，专注于研发、生产和销售外科手术、伤口护理、康复期护理类创新医疗产品，主要服务北美地区的医院、医疗机构及长期护理场所，旗下多款产品获FDA认证，旨在提升患者护理效果并降低医疗运营成本。
CLGN vs SMTI — 直观对比
营收规模更大
SMTI
是对方的153.7倍
$179.0K
营收增速更快
SMTI
高出32.7%
-28.1%
净利率更高
SMTI
高出1864.0%
-1869.8%
损益表 — Q2 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $179.0K | $27.5M |
| 净利润 | $-3.3M | $-1.6M |
| 毛利率 | -3.9% | 93.2% |
| 营业利润率 | -1775.4% | 23.5% |
| 净利率 | -1869.8% | -5.9% |
| 营收同比 | -28.1% | 4.6% |
| 净利润同比 | 20.5% | 5.3% |
| 每股收益（稀释后） | $0.28 | $-0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLGNSMTI
| Q4 25 | — | $27.5M | ||
| Q3 25 | — | $26.3M | ||
| Q2 25 | $179.0K | $25.8M | ||
| Q1 25 | — | $23.4M | ||
| Q4 24 | — | $26.3M | ||
| Q3 24 | — | $21.7M | ||
| Q2 24 | $249.0K | $20.2M | ||
| Q1 24 | — | $18.5M |
净利润CLGNSMTI
| Q4 25 | — | $-1.6M | ||
| Q3 25 | — | $-30.4M | ||
| Q2 25 | $-3.3M | $-2.0M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | — | $-2.9M | ||
| Q2 24 | $-4.2M | $-3.5M | ||
| Q1 24 | — | $-1.8M |
毛利率CLGNSMTI
| Q4 25 | — | 93.2% | ||
| Q3 25 | — | 92.9% | ||
| Q2 25 | -3.9% | 92.5% | ||
| Q1 25 | — | 92.2% | ||
| Q4 24 | — | 91.4% | ||
| Q3 24 | — | 90.8% | ||
| Q2 24 | -115.3% | 90.0% | ||
| Q1 24 | — | 89.8% |
营业利润率CLGNSMTI
| Q4 25 | — | 23.5% | ||
| Q3 25 | — | 11.2% | ||
| Q2 25 | -1775.4% | -0.1% | ||
| Q1 25 | — | -8.9% | ||
| Q4 24 | — | 18.6% | ||
| Q3 24 | — | 3.6% | ||
| Q2 24 | -1769.5% | -14.3% | ||
| Q1 24 | — | -8.3% |
净利率CLGNSMTI
| Q4 25 | — | -5.9% | ||
| Q3 25 | — | -115.5% | ||
| Q2 25 | -1869.8% | -7.8% | ||
| Q1 25 | — | -15.1% | ||
| Q4 24 | — | -6.5% | ||
| Q3 24 | — | -13.2% | ||
| Q2 24 | -1690.8% | -17.4% | ||
| Q1 24 | — | -9.5% |
每股收益（稀释后）CLGNSMTI
| Q4 25 | — | $-0.32 | ||
| Q3 25 | — | $-3.40 | ||
| Q2 25 | $0.28 | $-0.23 | ||
| Q1 25 | — | $-0.41 | ||
| Q4 24 | — | $-0.18 | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | $0.37 | $-0.41 | ||
| Q1 24 | — | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $11.4M | $16.6M |
| 总债务越低越好 | — | $46.0M |
| 股东权益账面价值 | $12.5M | $5.9M |
| 总资产 | $17.4M | $72.9M |
| 负债/权益比越低杠杆越低 | — | 7.74× |
8季度趋势，按日历期对齐
现金及短期投资CLGNSMTI
| Q4 25 | — | $16.6M | ||
| Q3 25 | — | $14.9M | ||
| Q2 25 | $11.4M | $17.0M | ||
| Q1 25 | — | $20.7M | ||
| Q4 24 | — | $15.9M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | $18.9M | $6.2M | ||
| Q1 24 | — | $2.8M |
总债务CLGNSMTI
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
股东权益CLGNSMTI
| Q4 25 | — | $5.9M | ||
| Q3 25 | — | $6.1M | ||
| Q2 25 | $12.5M | $35.4M | ||
| Q1 25 | — | $36.7M | ||
| Q4 24 | — | $39.4M | ||
| Q3 24 | — | $39.8M | ||
| Q2 24 | $20.7M | $41.7M | ||
| Q1 24 | — | $43.3M |
总资产CLGNSMTI
| Q4 25 | — | $72.9M | ||
| Q3 25 | — | $71.1M | ||
| Q2 25 | $17.4M | $98.8M | ||
| Q1 25 | — | $96.4M | ||
| Q4 24 | — | $88.1M | ||
| Q3 24 | — | $88.5M | ||
| Q2 24 | $26.6M | $73.4M | ||
| Q1 24 | — | $70.9M |
负债/权益比CLGNSMTI
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $3.9M |
| 自由现金流经营现金流 - 资本支出 | — | $3.9M |
| 自由现金流率自由现金流/营收 | — | 14.0% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $2.2M |
8季度趋势，按日历期对齐
经营现金流CLGNSMTI
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | $2.2M | ||
| Q2 25 | — | $2.7M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | — | $932.0K | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $-1.4M | ||
| Q1 24 | — | $-1.6M |
自由现金流CLGNSMTI
| Q4 25 | — | $3.9M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | — | $902.7K | ||
| Q1 25 | — | $-3.7M | ||
| Q4 24 | — | $859.9K | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | — | $-1.7M |
自由现金流率CLGNSMTI
| Q4 25 | — | 14.0% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | -15.9% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | — | 9.4% | ||
| Q2 24 | — | -7.3% | ||
| Q1 24 | — | -9.0% |
资本支出强度CLGNSMTI
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 0.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLGN
暂无分部数据
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
